This transcript has been edited for clarity.
The American Diabetes Association has recently released the 2022 Standards of Medical Care in Diabetes. Among the highlights are the use of sodium-glucose cotransporter 2 (SGLT2) inhibitors to slow the progression of kidney and cardiovascular disease, the use of nonsteroidal mineralocorticoid receptor agonists, such as finerenone, to slow progression of kidney disease, and the use of the new race-free equation that is currently being implemented by the National Kidney Foundation and the American Society of Nephrology.
The SGLT2 inhibitors have been shown to slow progression of kidney disease, decrease albuminuria, and have a cardiovascular benefit in patients with and without diabetes.
Chronic kidney disease affects 37 million Americans and 850 million people around the world. Diabetes is the most common cause of kidney disease in the United States. Unfortunately, chronic kidney disease is an asymptomatic disease, so symptoms only appear very late in the disease when people are already needing dialysis or transplantation.
Therefore, screening for chronic kidney disease in high-risk populations, such as those who have diabetes, hypertension, or a family history of kidney disease, is of vital importance. Unfortunately, not everybody who is at high risk is being screened; therefore, it's very important that when you discuss it with your provider, if you're at high risk, you at least have this test annually.
COMMENTARY
Managing Chronic Kidney Disease in Patients With Diabetes
Sylvia Rosas, MD, MSCE; Mark Harmel, MPH, CDCES
DisclosuresJune 09, 2022
This transcript has been edited for clarity.
The American Diabetes Association has recently released the 2022 Standards of Medical Care in Diabetes. Among the highlights are the use of sodium-glucose cotransporter 2 (SGLT2) inhibitors to slow the progression of kidney and cardiovascular disease, the use of nonsteroidal mineralocorticoid receptor agonists, such as finerenone, to slow progression of kidney disease, and the use of the new race-free equation that is currently being implemented by the National Kidney Foundation and the American Society of Nephrology.
The SGLT2 inhibitors have been shown to slow progression of kidney disease, decrease albuminuria, and have a cardiovascular benefit in patients with and without diabetes.
Chronic kidney disease affects 37 million Americans and 850 million people around the world. Diabetes is the most common cause of kidney disease in the United States. Unfortunately, chronic kidney disease is an asymptomatic disease, so symptoms only appear very late in the disease when people are already needing dialysis or transplantation.
Therefore, screening for chronic kidney disease in high-risk populations, such as those who have diabetes, hypertension, or a family history of kidney disease, is of vital importance. Unfortunately, not everybody who is at high risk is being screened; therefore, it's very important that when you discuss it with your provider, if you're at high risk, you at least have this test annually.
Medscape Diabetes © 2022 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: Managing Chronic Kidney Disease in Patients With Diabetes - Medscape - Jun 09, 2022.
Tables
Authors and Disclosures
Authors and Disclosures
Authors
Sylvia Rosas, MD, MSCE
Associate Professor of Medicine, Kidney and Hypertension Unit, Harvard Medical School; Director, Latino Kidney Clinic, Joslin Diabetes Center, Boston, Massachusettes
Disclosure: Sylvia E. Rosas, MD, has disclosed the following relevant financial relationships:
Serve(d) as a director, officer, partner, employee, advisor, consultant, or trustee for: National Kidney Foundation
Received research grant from: Bayer; AstraZeneca; MH/NDDK
Received income in an amount equal to or greater than $250 from: Bayer; AstraZeneca; Teladoc
Mark Harmel, MPH, CDCES
Clinical research coordinator, freelance videographer, Los Angeles, California
Disclosure: Mark Harmel, MPH, CDCES, has disclosed no relevant financial relationships.